CN113966221A - 合成溶瘤lnp复制子rna和用于癌症免疫治疗的用途 - Google Patents

合成溶瘤lnp复制子rna和用于癌症免疫治疗的用途 Download PDF

Info

Publication number
CN113966221A
CN113966221A CN202080034343.3A CN202080034343A CN113966221A CN 113966221 A CN113966221 A CN 113966221A CN 202080034343 A CN202080034343 A CN 202080034343A CN 113966221 A CN113966221 A CN 113966221A
Authority
CN
China
Prior art keywords
oncolytic virus
replicon rna
virus
synthetic oncolytic
synthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080034343.3A
Other languages
English (en)
Chinese (zh)
Inventor
D·J·欧文
K·D·维特鲁普
R·维斯
Y·栗
N·莫明
Y·董
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of CN113966221A publication Critical patent/CN113966221A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN202080034343.3A 2019-03-08 2020-01-10 合成溶瘤lnp复制子rna和用于癌症免疫治疗的用途 Pending CN113966221A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962815611P 2019-03-08 2019-03-08
US62/815,611 2019-03-08
PCT/US2020/013069 WO2020185293A1 (en) 2019-03-08 2020-01-10 Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy

Publications (1)

Publication Number Publication Date
CN113966221A true CN113966221A (zh) 2022-01-21

Family

ID=69526302

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080034343.3A Pending CN113966221A (zh) 2019-03-08 2020-01-10 合成溶瘤lnp复制子rna和用于癌症免疫治疗的用途

Country Status (13)

Country Link
US (2) US11717548B2 (US07342112-20080311-C00072.png)
EP (1) EP3934673A1 (US07342112-20080311-C00072.png)
JP (1) JP7561134B2 (US07342112-20080311-C00072.png)
KR (1) KR20220006041A (US07342112-20080311-C00072.png)
CN (1) CN113966221A (US07342112-20080311-C00072.png)
AU (1) AU2020233788A1 (US07342112-20080311-C00072.png)
BR (1) BR112021017637A8 (US07342112-20080311-C00072.png)
CA (1) CA3132714A1 (US07342112-20080311-C00072.png)
CO (1) CO2021013417A2 (US07342112-20080311-C00072.png)
IL (1) IL285963A (US07342112-20080311-C00072.png)
MX (1) MX2021010808A (US07342112-20080311-C00072.png)
SG (1) SG11202109514VA (US07342112-20080311-C00072.png)
WO (1) WO2020185293A1 (US07342112-20080311-C00072.png)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024027697A1 (zh) * 2022-08-05 2024-02-08 武汉滨会生物科技股份有限公司 包封的溶瘤病毒遗传物质及其应用
CN118147171A (zh) * 2024-03-08 2024-06-07 上海复诺健生物科技有限公司 具有增强的外源基因表达水平的自扩增mRNA核酸序列

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113509542A (zh) * 2021-04-20 2021-10-19 嘉晨西海(杭州)生物技术有限公司 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法
AU2023262576A1 (en) 2022-04-26 2024-10-10 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
WO2024149832A1 (en) * 2023-01-12 2024-07-18 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011005799A2 (en) * 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
CA2841047A1 (en) * 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
CA2893762A1 (en) * 2012-12-03 2014-06-12 Dipu Mohan-Kumar Ehrlichial invasin for immunization, diagnosis, and cell delivery
WO2016070136A1 (en) * 2014-10-31 2016-05-06 Massachusetts Institute Of Technology Delivery of biomolecules to immune cells
CN107072946A (zh) * 2014-09-05 2017-08-18 诺华股份有限公司 用于递送活性剂的脂质和脂质组合物
CN116710079A (zh) * 2020-07-24 2023-09-05 斯特兰德生物科技公司 包含经修饰的核苷酸的脂质纳米颗粒
CN117120446A (zh) * 2021-02-12 2023-11-24 俄亥俄州创新基金会 糖衍生的脂质纳米材料及其用途
CN117180454A (zh) * 2022-05-16 2023-12-08 上海行深生物科技有限公司 含有自复制rna分子和脂质纳米颗粒递送载体的组合物及其制备方法
CN117897494A (zh) * 2021-07-09 2024-04-16 瑞普利科特生物科学公司 经修饰的东方马脑炎病毒、自复制rna构建体及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
BR112013000392B8 (pt) * 2010-07-06 2022-10-04 Novartis Ag Composição farmacêutica contendo partícula de distribuição semelhante a vírion para moléculas de rna autorreplicantes e seu uso
US10369122B2 (en) 2015-05-21 2019-08-06 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derivatives and uses thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011005799A2 (en) * 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
CA2841047A1 (en) * 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
CA2893762A1 (en) * 2012-12-03 2014-06-12 Dipu Mohan-Kumar Ehrlichial invasin for immunization, diagnosis, and cell delivery
CN107072946A (zh) * 2014-09-05 2017-08-18 诺华股份有限公司 用于递送活性剂的脂质和脂质组合物
WO2016070136A1 (en) * 2014-10-31 2016-05-06 Massachusetts Institute Of Technology Delivery of biomolecules to immune cells
CN116710079A (zh) * 2020-07-24 2023-09-05 斯特兰德生物科技公司 包含经修饰的核苷酸的脂质纳米颗粒
CN117120446A (zh) * 2021-02-12 2023-11-24 俄亥俄州创新基金会 糖衍生的脂质纳米材料及其用途
CN117897494A (zh) * 2021-07-09 2024-04-16 瑞普利科特生物科学公司 经修饰的东方马脑炎病毒、自复制rna构建体及其用途
CN117180454A (zh) * 2022-05-16 2023-12-08 上海行深生物科技有限公司 含有自复制rna分子和脂质纳米颗粒递送载体的组合物及其制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IAN LAI等: "Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma", 《JOURNAL FOR IMMUNOTHERAPY OF CANCER》, 20 November 2018 (2018-11-20) *
KENNETH LUNDSTROM: "Replicon RNA Viral Vectors as Vaccines", 《VACCINES》, 7 November 2016 (2016-11-07) *
MATTHIAS A. OBERLI等: "Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy", 《NANO LETT.》, 23 November 2016 (2016-11-23) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024027697A1 (zh) * 2022-08-05 2024-02-08 武汉滨会生物科技股份有限公司 包封的溶瘤病毒遗传物质及其应用
CN118147171A (zh) * 2024-03-08 2024-06-07 上海复诺健生物科技有限公司 具有增强的外源基因表达水平的自扩增mRNA核酸序列

Also Published As

Publication number Publication date
CO2021013417A2 (es) 2022-01-17
KR20220006041A (ko) 2022-01-14
WO2020185293A1 (en) 2020-09-17
US20200281994A1 (en) 2020-09-10
CA3132714A1 (en) 2020-09-17
US11717548B2 (en) 2023-08-08
BR112021017637A2 (US07342112-20080311-C00072.png) 2021-11-09
US20240024394A1 (en) 2024-01-25
IL285963A (en) 2021-10-31
SG11202109514VA (en) 2021-09-29
AU2020233788A1 (en) 2021-10-07
MX2021010808A (es) 2021-12-15
JP2022524391A (ja) 2022-05-02
BR112021017637A8 (pt) 2022-08-16
JP7561134B2 (ja) 2024-10-03
EP3934673A1 (en) 2022-01-12

Similar Documents

Publication Publication Date Title
CN113966221A (zh) 合成溶瘤lnp复制子rna和用于癌症免疫治疗的用途
CN112584849B (zh) 包含核酸及car修饰的免疫细胞的治疗剂及其应用
RU2744603C2 (ru) Композиции, повышающие число копий вектора (чкв), и способы их применения
CA2447450C (en) Corona-virus-like particles comprising functionally deleted genomes
KR101255419B1 (ko) 인플루엔자 바이러스의 다중 아형에 대한 신규 백신
KR20210043574A (ko) 푸소좀 조성물 및 이의 용도
AU2023214288A1 (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
CN105765062B (zh) 丝裂原活化蛋白激酶依赖性重组痘苗病毒(md-rvv)及其应用
CN107746845B (zh) 特异性靶向LAG-3基因的sgRNA和特异性敲除LAG-3基因的方法
CN109640946A (zh) 通过基因编辑策略进行hiv-1的负反馈调节
AU2017248259A1 (en) Chimeric antigen receptor T cell compositions
KR20210154176A (ko) 표적화된 생체내 후성유전학적 억제에 의한 장기지속성 진통
RU2771383C2 (ru) Контролируемая пищевым рационом экспрессия нуклеиновой кислоты, кодирующей нуклеазу cas9, и ее применения
KR20200089289A (ko) 비골수제거 골수 재건을 위한 방법 및 조성물
CN108379597B (zh) 一种基因载体及其用于治疗视网膜神经节细胞变性的基因治疗药物
SA519401615B1 (ar) لقاح dna مُولِد للتحمل
KR102679920B1 (ko) 모노머형 스트렙타비딘을 발현하는 균주 및 비오틴화된 화합물을 포함하는 암 세포 표적용 조성물
CN107760680B (zh) 特异性靶向TIM-3基因的sgRNA和特异性敲除TIM-3基因的方法
KR20240022575A (ko) 아머링된 키메라 수용체 및 이의 사용 방법
KR20210102247A (ko) Crispr 수퍼-리프레서에 의한 생체내 합성 면역조절
CN112725344B (zh) 密码子优化的smn1基因、腺相关病毒表达质粒及基因药物
RU2809724C2 (ru) Синтетический онколитический lnp-репликон рнк и применения для иммунотерапии злокачественных опухолей
CN112342231A (zh) 一种不耐热ung融合蛋白的重组载体及表达纯化方法
CN115298307A (zh) 核酸调节元件的新组合及其方法和用途
CN114008209A (zh) Aav介导的枫糖尿症(msud)基因疗法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination